Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells

Marco Iannetta, Giuseppe Ippolito, Emanuele Nicastri
Marco Iannetta
National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marco Iannetta
Giuseppe Ippolito
National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emanuele Nicastri
National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01152-17
  • Article
  • Info & Metrics
  • PDF
Loading

LETTER

We read with interest the manuscript by Saiz and Martín-Acebes (1) on the candidate drugs with in vitro anti-Zika virus activity. The drugs presented in that review belong to several classes, such as antibiotic, antiviral, antimalarial, and antiparasitic agents, immunosuppressant and immunomodulating drugs, proteasome inhibitors, antidepressants, antiemetic agents, cyclin-dependent kinase inhibitors, apoptosis-related drugs, and hypolipidemic agents (1). Among the antibiotics with an in vitro anti-Zika activity, the authors cited nanchangmycin, daptomicin, and kitasamycin, without mentioning azithromycin (an antibiotic of the macrolide family). Indeed, in vitro data recently published by Retallack et al. showed that azithromycin was able to reduce the infection rate of U87 cells (a human glioblastoma astrocytoma cell line), to rescue cell viability, and to decrease viral production (2). Although the mechanism of action of azithromycin in inhibiting Zika virus infection of target cells and viral production is still unknown, similar results were obtained using human pluripotent stem cell (hPSC)-derived neural cells infected with Zika virus (2). In vitro, azithromycin inhibition activity against Zika virus infection of U87 cells was compared to those of daptomycin and sofosbuvir, two promising candidates that show anti-Zika activities and are considered safe in pregnancy. It was found that azithromycin and sofosbuvir decreased the proportion of infected cells to below 5%, while daptomycin was unable to decrease the infection rate below 46% in this experimental model, even at the highest dose (2). Considering the demonstrated antiviral activity in human glial cells, azithromycin represents a candidate molecule for preventing Zika virus-induced alterations of fetal brain. In addition, azithromycin is considered safe during pregnancy and is classified among the FDA category B drugs (3). Pharmacokinetic studies have demonstrated a rapid uptake of this antibiotic in placental tissue (4) and accumulation in human brain (5). Azithromycin represents an interesting and promising molecule for the treatment of Zika virus infections. Besides the antiviral activity demonstrated on human primary cell and cell line cultures, this drug is also a widely diffused and inexpensive antibiotic, available in oral and intravenous formulations. Furthermore, its use is already approved in humans and pregnant women. All these elements strongly support a repurposing approach for azithromycin as an anti-Zika drug for the treatment of infected men as well as infected women, especially during pregnancy. Further studies involving Zika virus-infected individuals are needed and recommended in order to confirm in vivo the results previously obtained with in vitro experimental models.

FOOTNOTES

  • For the author reply, see https://doi.org/10.1128/AAC.01192-17.

  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Saiz JC,
    2. Martín-Acebes MA
    . 2017. The race to find antivirals for Zika virus. Antimicrob Agents Chemother61:e00411-17. doi:10.1128/AAC.00411-17.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Retallack H,
    2. Di Lullo E,
    3. Arias C,
    4. Knopp KA,
    5. Laurie MT,
    6. Sandoval-Espinosa C,
    7. Mancia Leon WR,
    8. Krencik R,
    9. Ullian EM,
    10. Spatazza J,
    11. Pollen AA,
    12. Mandel-Brehm C,
    13. Nowakowski TJ,
    14. Kriegstein AR,
    15. DeRisi JL
    . 2016. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A113:14408–14413. doi:10.1073/pnas.1618029113.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Lin KJ,
    2. Mitchell AA,
    3. Yau W-P,
    4. Louik C,
    5. Hernández-Díaz S
    . 2013. Safety of macrolides during pregnancy. Am J Obstet Gynecol208:221.e1–221.e8. doi:10.1016/j.ajog.2012.12.023.
    OpenUrlCrossRef
  4. 4.↵
    1. Ramsey PS,
    2. Vaules MB,
    3. Vasdev GM,
    4. Andrews WW,
    5. Ramin KD
    . 2003. Maternal and transplacental pharmacokinetics of azithromycin. Am J Obstet Gynecol188:714–718. doi:10.1067/mob.2003.141.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Jaruratanasirikul S,
    2. Hortiwakul R,
    3. Tantisarasart T,
    4. Phuenpathom N,
    5. Tussanasunthornwong S
    . 1996. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob Agents Chemother40:825–826.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells
Marco Iannetta, Giuseppe Ippolito, Emanuele Nicastri
Antimicrobial Agents and Chemotherapy Aug 2017, 61 (9) e01152-17; DOI: 10.1128/AAC.01152-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells
Marco Iannetta, Giuseppe Ippolito, Emanuele Nicastri
Antimicrobial Agents and Chemotherapy Aug 2017, 61 (9) e01152-17; DOI: 10.1128/AAC.01152-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • FOOTNOTES
    • REFERENCES
  • Info & Metrics
  • PDF

KEYWORDS

azithromycin
Zika virus
Zika virus
antiviral agents
azithromycin
central nervous system infections
pregnancy

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596